The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis

about

The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis

Item

http://www.wikidata.org/entity/Q58698737

description

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 24 October 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

The efficacy and safety of imm ...... matic review and meta-analysis

@en

The efficacy and safety of imm ...... matic review and meta-analysis

@nl

type

Item

label

The efficacy and safety of imm ...... matic review and meta-analysis

@en

The efficacy and safety of imm ...... matic review and meta-analysis

@nl

prefLabel

The efficacy and safety of imm ...... matic review and meta-analysis

@en

The efficacy and safety of imm ...... matic review and meta-analysis

@nl

P1476

The efficacy and safety of imm ...... matic review and meta-analysis

@en

P2093

Gu Lei

http://www.w3.org/2001/XMLSchema#string

Meng Xue Hu

http://www.w3.org/2001/XMLSchema#string

Min Peng

http://www.w3.org/2001/XMLSchema#string

Qi Bin Song

http://www.w3.org/2001/XMLSchema#string

Xing Li

http://www.w3.org/2001/XMLSchema#string

Yi Ming Weng

http://www.w3.org/2001/XMLSchema#string

P2860

Immune Checkpoint Blockade in Cancer Therapy

Global cancer statistics, 2012

The blockade of immune checkpoints in cancer immunotherapy

The future of immune checkpoint therapy

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

P304

7369-7383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S177318

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30425525

http://www.w3.org/2001/XMLSchema#string

P932

6204847

http://www.w3.org/2001/XMLSchema#string